Cartesian Therapeutics (NASDAQ:RNAC) Price Target Lowered to $40.00 at Needham & Company LLC
Needham & Company lowered its Cartesian Therapeutics (NASDAQ: RNAC) price target to $40 from $42 while keeping a “buy” rating, according to a Tuesday note reported by Benzinga. RNAC traded at $6.38, down 5.5%. The company reported Q1 EPS of -$1.46 and revenue of $0.08M, missing consensus.
How this was made
The 30-second read
Why it matters
The key tradable signal is the research target cut (Needham) alongside a recent earnings miss (EPS and revenue), which together can pressure sentiment and raise scrutiny on near-term progress.
Market read
This is a sentiment/valuation update for RNAC with limited magnitude, but it arrives after a notable earnings shortfall and amid mixed analyst ratings.
What to watch
The article emphasizes hedge-fund ownership being heavily institutional; flows and upcoming clinical/financing catalysts (not discussed here) may matter more than this target change.
Background
Cartesian Therapeutics is a clinical-stage mRNA therapeutics company using a proprietary RNA delivery/LNP platform.
Ticker impact
Needham lowered its RNAC target from $42 to $40 while keeping a Buy rating, signaling a modest valuation reset after recent performance.
Likely limited near-term upside from the target cut; focus may shift to upcoming catalysts rather than analyst price levels.
The article is primarily a research-target update (small reduction) and does not cite new RNAC fundamentals; however, it also highlights a significant EPS and revenue miss on April 30, which can dominate price action.
Market effects
Biotech/mRNA names may see sentiment swings when analyst targets are trimmed despite Buy calls, especially after earnings misses.
Primarily US small-cap biotech sentiment; limited direct regional spillover implied.
Low—no international deal/regulatory catalyst mentioned.
Counterpoint
A small target reduction with a Buy rating can be read as analysts still expect eventual de-risking, making the move less bearish than it appears.
Key entities
- companyCartesian Therapeutics
RNAC; Needham reduced its target to $40 and the company recently missed EPS and revenue expectations.
- research_firmNeedham & Company LLC
Lowered RNAC target from $42 to $40 while maintaining a Buy rating.
